We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accenture (ACN) Set to Invest in Titan Space Technologies
Read MoreHide Full Article
Accenture plc (ACN - Free Report) announced yesterday that it has made a strategic investment in orbital compute platform, Titan Space Technologies, through Accenture Ventures, its venture arm. Financial terms have been kept under wraps.
Founded in 2021, Titan Space Technologies is a provider of real-time monitoring and neural engine capabilities.
Titan Joins Project Spotlight
Titan is now a participant in Accenture Ventures’ Project Spotlight, an engagement and investment program aimed at providing emerging technology software startups access to Accenture’s technological and domain expertise across its G2000 client base.
Through the strategic investment, Accenture aims at accelerating scientific technology innovations for enterprises, such as biomedical applications, carbon capture and adaptive immune response.
Tom Lounibos, managing director, Accenture Ventures noted, "The burgeoning private and commercial space sector has created a once-in-a-generation opportunity for companies to leverage the unique R&D environment of space along with ever-increasingly sophisticated AI and other technologies to potentially solve our most pressing issues here on earth such as climate change, disease interventions, and materials shortages."
Notably, Accenture’s shares have gained 19.6% over the past year, outperforming the 9.8% rise of the Zacks S&P 500 composite while underperforming the 21.6% growth of the industry it belongs to.
Cross Country Healthcare has an expected long-term earnings per share (three to five years) growth rate of 6.6%. CCRN has a trailing four-quarter earnings surprise of 41.5%, on average.
Cross Country Healthcare’s shares have surged 56% in the past year. CCRN sports a Zacks Rank #1 (Strong Buy).
FactSet has an expected earnings growth rate of around 15.1% for the current year. FDS has a trailing four-quarter earnings surprise of 6.1%, on average.
FactSet shares have surged 42.7% in the past year. FDS has a long-term earnings growth of 10%. FDS carries a Zacks Rank #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Accenture (ACN) Set to Invest in Titan Space Technologies
Accenture plc (ACN - Free Report) announced yesterday that it has made a strategic investment in orbital compute platform, Titan Space Technologies, through Accenture Ventures, its venture arm. Financial terms have been kept under wraps.
Founded in 2021, Titan Space Technologies is a provider of real-time monitoring and neural engine capabilities.
Titan Joins Project Spotlight
Titan is now a participant in Accenture Ventures’ Project Spotlight, an engagement and investment program aimed at providing emerging technology software startups access to Accenture’s technological and domain expertise across its G2000 client base.
Through the strategic investment, Accenture aims at accelerating scientific technology innovations for enterprises, such as biomedical applications, carbon capture and adaptive immune response.
Tom Lounibos, managing director, Accenture Ventures noted, "The burgeoning private and commercial space sector has created a once-in-a-generation opportunity for companies to leverage the unique R&D environment of space along with ever-increasingly sophisticated AI and other technologies to potentially solve our most pressing issues here on earth such as climate change, disease interventions, and materials shortages."
Notably, Accenture’s shares have gained 19.6% over the past year, outperforming the 9.8% rise of the Zacks S&P 500 composite while underperforming the 21.6% growth of the industry it belongs to.
Accenture PLC Price
Accenture PLC price | Accenture PLC Quote
Zacks Rank and Stocks to Consider
Accenture currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks in the broader Zacks Business Services sector are FactSet Research Systems Inc. (FDS - Free Report) and Cross Country Healthcare, Inc. (CCRN - Free Report) .
Cross Country Healthcare has an expected long-term earnings per share (three to five years) growth rate of 6.6%. CCRN has a trailing four-quarter earnings surprise of 41.5%, on average.
Cross Country Healthcare’s shares have surged 56% in the past year. CCRN sports a Zacks Rank #1 (Strong Buy).
FactSet has an expected earnings growth rate of around 15.1% for the current year. FDS has a trailing four-quarter earnings surprise of 6.1%, on average.
FactSet shares have surged 42.7% in the past year. FDS has a long-term earnings growth of 10%. FDS carries a Zacks Rank #2 (Buy).